^
Association details:
| Biomarker: | IDH1 mutation + ATRX deletion + TP53 deletion |
|---|---|
| Cancer: | Glioma |
| Drug: | CAN-3110 (Cytotoxic T lymphocyte stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Oncolytic HSV-1 rQNestin34.5v2 Sensitizes IDH1-mutated Glioma to Immunotherapy
Published date:
05/03/2022
Excerpt:
The antitumor activity of this HSV-1 was evaluatedin C57BL/6 mice harboring orthotopic glioma expressing mutant and wild type IDH1 with loss of ATRX and TP53. HSV-1 rQNestin34.5v2 infected wild type and mIDH1 murine glioma cells in vitrotriggering cytotoxicity and release of proinflammatory chemokines in infectedcells. Mice harboring mIDH1 gliomas exhibited a less aggressive phenotype and significantly longer survival period compared to those with IDH1 wild type gliomas.
